Therapy-activated stromal cells can dictate tumor fate

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy

(2016) Y. Shaked et al.   CANCER RESEARCH

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00

(2016) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

(2016) Tze-Sian Chan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

(2016) Yuval Shaked   Nature Reviews Clinical Oncology

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

Rationale for metronomic chemotherapy in phase III trials

(2015) Robert S. Kerbel et al.   Nature Reviews Clinical Oncology

Clinical overview of metronomic chemotherapy in breast cancer

(2015) Elisabetta Munzone et al.   Nature Reviews Clinical Oncology

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

(2013) Marta Vives et al.   INTERNATIONAL JOURNAL OF CANCER

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology

Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1

(2009) C. Folkins et al.   CANCER RESEARCH